Efficacy and Tolerance of Urea Compared with Vaptans for Long-Term Treatment of Patients with SIADH
Open Access
- 1 May 2012
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 7 (5), 742-747
- https://doi.org/10.2215/cjn.06990711
Abstract
Background and objectives Vaptans (vasopressin V2-receptor antagonists) are a new approach for the treatment of hyponatremia. However, their indications remain to be determined, and their benefit compared with that of the usual treatments for the syndrome of inappropriate antidiuretic hormone secretion (SIADH) have not been evaluated. This prospective, long-term study compared the efficacy, tolerability, and safety of two oral vaptans with those of oral urea in patients with SIADH. Design, setting, participants, & measurements Patients with chronic SIADH of various origins were treated first with vaptans for 1 year. After an 8-day holiday period, they received oral urea for an additional 1-year follow-up. Serum sodium was measured every 2 months, and drug doses were adjusted accordingly. Results Thirteen participants were initially included in the study (serum sodium, 125±3 mEq/L); 12 completed the 2-year treatment period. Treatment with vaptans (satavaptan, 5–50 mg/d, n=10; tolvaptan, 30–60 mg/day, n=2) increased natremia (serum sodium, 135±3 mEq/L) during the 1-year vaptan period without escape. Hyponatremia recurred in the 12 participants when vaptans were stopped (holiday period). Urea improved the natremia with the same efficacy (serum sodium, 135±2 mEq/L) as vaptans during the 1-year urea treatment period. One participant treated with tolvaptan withdrew from the study early because of excessive thirst. Another patient receiving urea developed hypernatremia without complications. Conclusions Urea has efficacy similar to that of vaptans for treatment of chronic SIADH. Tolerance is generally good for both agents.This publication has 46 references indexed in Scilit:
- Mortality and Serum SodiumClinical Journal of the American Society of Nephrology, 2011
- Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretionActa Endocrinologica, 2011
- Oral Tolvaptan Is Safe and Effective in Chronic HyponatremiaJournal of the American Society of Nephrology, 2010
- Hyponatremia Independent of Osteoporosis is Associated with Fracture OccurrenceClinical Journal of the American Society of Nephrology, 2010
- Hyponatremia-induced osteoporosisJournal of Bone and Mineral Research, 2010
- Treatment of euvolemic hyponatremia in the intensive care unit by ureaCritical Care, 2010
- Current and future treatment options in SIADHClinical Kidney Journal, 2009
- Mild hyponatremia and risk of fracture in the ambulatory elderlyQJM: An International Journal of Medicine, 2008
- Oral Urea for the Treatment of Chronic Syndrome of Inappropriate Antidiuresis in ChildrenThe Journal of Pediatrics, 2006
- HyponatremiaThe New England Journal of Medicine, 2000